As the drug discovery business goes through difficult times, drug candidates can't seem to move through the pharmaceutical industry process fast enough. As well, entrepreneurs are struggling to get the funding they need to carry through their ideas to fruition. Can partnerships between big pharma and academia help? With the many recent cases of new alliances and partnerships in the works, it appears that many big pharma companies think so. Comment below and let us know what you think.
Boehringer Ingelheim announced that it has established a translational research collaboration with the Presidents and Fellows of Harvard College. The goal of the collaboration is for the scientists of Boehringer Ingelheim to work together with the scientific community of Harvard to advance knowledge in areas of high unmet medical need. The focus of the different research projects is to identify and investigate novel signaling pathways and drug targets in oncology, cardiometabolic, fibrotic and infectious diseases.
The University of Cambridge begins a new collaboration with GlaxoSmithKline to advance drug discovery and the development of new medicines. The collaboration will see researchers from both sides working together at the Stevenage Bioscience Catalyst, the UK's first open innovation bioscience campus, co-located with GSK's R&D centre. This bioscience park provides an independent scientific community allowing scientists to foster relationships across organisations and share their expertise and knowledge.
Bristol-Myers Squibb (NYSE: BMY) entered into a strategic partnership with Emory University to conduct clinical trials involving Bristol-Myers Squibb's investigational compounds. No specific project details were revealed. Under the newly established Master Clinical Trial Agreement, investigators from Emory University and affiliated institutions will conduct Phase II, Phase III and pediatric clinical trials in the metropolitan Atlanta area to support the ongoing development of investigational medicines from across B-MS' portfolio, particularly in oncology, metabolics, hepatitis C and immunoscience. This agreement builds on recent experiences between the two organizations in conducting clinical trials in organ transplantation and cancer.
Do you have any to add? Comment below.
Are you an expert in the field of biopharma partnerships and investment? Contact Justine Williams at email@example.com for guest blogging opportunities.
For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D